Ask AI
ProCE Banner Series

State-of-the-Art Care in CLL/SLL: Best Practices in an Expanding Therapeutic Landscape

Join us for this 1-hour webinar with a live Q&A session where experts discuss the latest data on their approaches to caring for patients with CLL/SLL, including information on management of treatment-naive and relapsed/refractory CLL/SLL.

  ACPE-P
Credits Available


Who Should Attend

Pharmacists, including clinical and health-system, ambulatory care, and community pharmacists, who care for patients with CLL/SLL, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in health-system pharmacy.

All Events

Past Events

January

19

2023

Thursday, January 19, 2023 - State-of-the-Art Care in CLL/SLL: Best Practices in an Expanding Therapeutic Landscape

3:00 PM - 4:00 PM Eastern Time (ET)

Virtual

January

25

2023

Wednesday, January 25, 2023 - State-of-the-Art Care in CLL/SLL: Best Practices in an Expanding Therapeutic Landscape

6:00 PM - 7:00 PM Eastern Time (ET)

Virtual

January

31

2023

Tuesday, January 31, 2023 - State-of-the-Art Care in CLL/SLL: Best Practices in an Expanding Therapeutic Landscape

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Topics


Additional Info


CME/CE Info

Program Overview
This program presents the latest clinical data to aid pharmacists in providing optimal care for their patients with CLL/SLL, including downloadable slides from the live, 1-hour webinars, and ClinicalThought commentaries with key take-home points and FAQs from the webinars.

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of pharmacists in the management of patients with CLL/SLL.

Target Audience
The target audience is pharmacists, including clinical and health-system, ambulatory care, and community pharmacists, who care for patients with CLL/SLL, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in health-system pharmacy.

Learning Objectives
Upon completion of this activity, participants should be able to:

  1. Apply current evidence and guidelines for the treatment and management of treatment-naive and relapsed/refractory CLL/SLL, taking into consideration the agent’s toxicity profile, prognostic variables, comorbidities, and patient preference
  2. Foster collaborative discussions between patients, caregivers, and healthcare professionals to guide personalized treatment planning
  3. Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles among agents used to treat CLL/SLL
  4. Evaluate strategies to proactively mitigate and manage treatment-related adverse events that occur with current and emerging approaches

Accreditation

CE Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-23-002-L01-P has been assigned to this live application-based activity (initial release date 01/19/2023). This activity is approved for 1.0 contact hour (0.1 CEUs) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.proce.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.

Acknowledgement

Provided by ProCE, LLC.

Supported by educational grants from Genentech, a member of the Roche Group and AstraZeneca.